Posts by Peptra Labs Research
Retatrutide TRIUMPH-1: 80-Week Phase 3 Findings
What a new 80-week phase 3 trial reported about retatrutide, body weight, knee osteoarthritis and obstructive sleep apnoea.
Retatrutide in TRIUMPH-2: 80-Week Phase 3 Results
What the TRIUMPH-2 phase 3 trial reported about retatrutide in adults with obesity and type 2 diabetes, including weight change and safety findings.
Tirzepatide vs Semaglutide: What a 2026 Comparison Found
A 2026 indirect comparison associated tirzepatide with greater weight reduction than semaglutide, while highlighting the limits of cross-trial evidence.
GLP-1 RAs in Lumbar Fusion: 7 Cohorts Reviewed
GLP-1 receptor agonist exposure before lumbar fusion showed no statistically significant increase in the reviewed postoperative outcomes.
Semaglutide Oral: 2026 Claims Cohort
Semaglutide oral was associated with lower cardiovascular outcome rates in a claims-data cohort, but its observational design cannot establish causation.
Semaglutide in HIV: 108 Participants, 32 Weeks
Semaglutide did not change the trial's measured vascular markers over 32 weeks, while ASCVD risk score and hsCRP differed from placebo.
Retatrutide in PWS: One 18-Month Case
Retatrutide began a sequential incretin case report in Prader-Willi syndrome, but the 18-month result cannot isolate one compound's contribution.
Semaglutide in DKD: 10 Randomized Datasets
Semaglutide was one of several interventions assessed across 10 randomized datasets in a new diabetic kidney disease network meta-analysis.
Semaglutide: SELECT Results by Frailty Status
Semaglutide showed no detectable difference in SELECT cardiovascular results across baseline frailty categories in a new post-hoc analysis.
Tirzepatide in HS: Signals From a TriNetX Cohort
Tirzepatide or GLP-1RA exposure was associated with different two-year outcomes in a matched hidradenitis suppurativa cohort.